The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction

CONCLUSIONS: The treatment of HFpEF has made progress, but there is still work to be done. Now, SGLT2 inhibitor therapy can be used to further help with symptom control and reduce overall hospitalizations for heart failure.PMID:37542422 | DOI:10.1177/10600280231189508
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Source Type: research